Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110776 | 0.85 | RPS6KA2 (0.31) | RPS6KA2 | |
| SCHEMBL1986577 | 0.76 | GSK3B (0.43) | MAPT | |
| SCHEMBL1841985 | 0.76 | KDM4E (0.44) | MAPTKDM4E | |
| SCHEMBL13623804 | 0.76 | HCAR3 (0.42) | MAPTKDM4EEGLN1 | |
| SCHEMBL29129120 | 0.73 | ADORA3 (0.41) | MAPT | |
| SCHEMBL2450183 | 0.73 | GRN (0.44) | KDM4EGRNSORT1 | |
| SCHEMBL2389887 | 0.72 | GSK3B (0.40) | RPS6KA2 | |
| SCHEMBL2390936 | 0.72 | GSK3B (0.40) | RPS6KA2 | |
| SCHEMBL20796574 | 0.72 | HDAC1 (0.42) | RPS6KA2MAPTKDM4E | |
| SCHEMBL14388704 | 0.71 | NAMPT (0.48) | RPS6KA2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | TOP2A 4867/4885RPS6KA2 2975/4885MAPT 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.